%D8%AC%D9%8A%D9%85%D8%B3_%D8%A3%D9%84%D9%8A%D8%B3%D9%88%D9%86%E0%A6%9C%E0%A7%87%E0%A6%AE%E0%A6%9B_%E0%A6%AA%E0%A6%BF._%E0%A6%8F%E0%A6%B2%E0%A6%BF%E0%A6%9A%E0%A6%A8James_P._Allison%D0%94%D0%B6%D1%8D%D0%B9%D0%BC%D1%81_%D0%AD%D0%BB%D1%96%D1%81%D0%B0%D0%BD%D0%94%D0%B6%D0%B5%D0%B9%D0%BC%D1%81_%D0%90%D0%BB%D0%B8%D1%81%D1%8A%D0%BD%E0%A6%9C%E0%A7%87%E0%A6%AE%E0%A6%B8_%E0%A6%AA%E0%A6%BF._%E0%A6%8F%E0%A6%B2%E0%A6%BF%E0%A6%B8%E0%A6%A8Category:James_P._AllisonJames_P._AllisonJames_P._AllisonJames_P._AllisonJames_P._AllisonJames_P._AllisonJames_P._Allison%D8%AC%DB%8C%D9%85%D8%B2_%D9%BE%DB%8C._%D8%A7%D9%84%DB%8C%D8%B3%D9%86James_P._AllisonJames_Allison_(immunologiste)%D7%92%27%D7%99%D7%99%D7%9E%D7%A1_%D7%90%D7%9C%D7%99%D7%A1%D7%95%D7%9FJames_AllisonJames_P._AllisonJames_Patrick_AllisonJames_Patrick_Allison%E3%82%B8%E3%82%A7%E3%83%BC%E3%83%A0%E3%82%BA%E3%83%BBP%E3%83%BB%E3%82%A2%E3%83%AA%E3%82%BD%E3%83%B3James_P_Allison%EC%A0%9C%EC%9E%84%EC%8A%A4_P._%EC%95%A8%EB%A6%AC%EC%8A%A8Iacobus_Allison%E0%B4%9C%E0%B5%86%E0%B4%AF%E0%B4%BF%E0%B4%82%E0%B4%B8%E0%B5%8D_%E0%B4%AA%E0%B4%BF_%E0%B4%86%E0%B4%B2%E0%B4%BF%E0%B4%B8%E0%B5%BAJames_P._AllisonJames_Patrick_AllisonJames_Allison%E0%A8%9C%E0%A9%87%E0%A8%AE%E0%A8%9C%E0%A8%BC_%E0%A8%AA%E0%A9%80._%E0%A8%90%E0%A8%B2%E0%A9%80%E0%A8%B8%E0%A8%A8James_P._AllisonJames_Patrick_AllisonJames_P._Allison%D0%9A%D0%B0%D1%82%D0%B5%D0%B3%D0%BE%D1%80%D0%B8%D1%8F:%D0%94%D0%B6%D0%B5%D0%B9%D0%BC%D1%81_%D0%AD%D0%BB%D0%BB%D0%B8%D1%81%D0%BE%D0%BD%D0%AD%D0%BB%D0%BB%D0%B8%D1%81%D0%BE%D0%BD,_%D0%94%D0%B6%D0%B5%D0%B9%D0%BC%D1%81James_P._AllisonJames_P._Allison%E0%AE%9A%E0%AF%87%E0%AE%AE%E0%AF%8D%E0%AE%9A%E0%AF%81_%E0%AE%86%E0%AE%B2%E0%AE%BF%E0%AE%9A%E0%AE%A9%E0%AF%8D%D2%96%D0%B5%D0%B9%D0%BC%D1%81_%D0%9F%D0%B0%D1%82%D1%80%D0%B8%D0%BA_%D3%98%D0%BB%D0%BB%D0%B8%D1%81%D0%BE%D0%BD%D0%94%D0%B6%D0%B5%D0%B9%D0%BC%D1%81_%D0%95%D0%BB%D0%BB%D1%96%D1%81%D0%BE%D0%BD
about
sameAs
Cancer classification using the Immunoscore: a worldwide task forceFc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanomaPD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cellsCD28 and CTLA-4 have opposing effects on the response of T cells to stimulationCancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaB7x: a widely expressed B7 family member that inhibits T cell activationEmerging mechanisms of immune regulation: the extended B7 family and regulatory T cellsStrategies for combining immunotherapy with radiation for anticancer therapyCombining radiation and immunotherapy: a new systemic therapy for solid tumors?Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surfaceCD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clonesThe future of immune checkpoint therapyCo-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamilyEnhancement of antitumor immunity by CTLA-4 blockadeRestoring function in exhausted CD8 T cells during chronic viral infectionBTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine productionPD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsImmunologic correlates of the abscopal effect in a patient with melanomaProgrammed death-1 concentration at the immunological synapse is determined by ligand affinity and availability.Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses.CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1.A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors.Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesCostimulatory regulation of T cell function.Attenuated T cell responses to a high-potency ligand in vivo.Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsInhibitors of B7-CD28 costimulation in urologic malignancies.Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection.Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c miceTCR ligand density and affinity determine peripheral induction of Foxp3 in vivo.Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survivalSerum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stagePreoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer.Retrospective. Lloyd J. Old (1933-2011).Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survivalTumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas.
P50
Q21245495-720CCF03-41CD-4D28-957D-DC1134B468A5Q24629841-A7EBD6F5-9482-4759-B2F7-418102A445CEQ24677367-14645D9E-71EC-46EA-AC91-E8A0F935B2D0Q24678846-25c62bdb-42b3-8b02-61fa-bc8a35257169Q24679736-B95BD291-87DF-4C58-B34A-B05535DB6298Q24683252-2F6E6373-6CE5-43F2-8F01-0B72FE50C597Q24796946-00314A52-880D-427A-B99B-E346E012C0F7Q26796675-C90A12CD-FBE9-43D8-9038-B5E805263F84Q26991721-3EFCF7E8-D443-419B-8413-FDB156A2DB4EQ27345462-4ACECD66-A1E3-4A55-AD64-ADBC19037758Q27644083-833A2DBF-54D6-441A-86B4-705CE5D3E4F0Q28209894-aa48daa4-4c64-34df-ed22-2ab6b2f1d198Q28259862-2A8E9CDC-21B4-400D-BFD0-9337F36B21B3Q28271806-854F2BAC-026B-4A82-AA9B-0CC1DD724322Q28275730-70f29990-4c5a-355f-70fd-1076651a3c7dQ28289222-CFFC78CA-A956-4AA8-9681-EC92A4E25B20Q28589743-0F802B91-C3CC-4235-9C82-4205C7CAA581Q28740530-7FBB19F0-DD51-4E24-98CE-2E63F7B73E6DQ29619686-4ca094ea-4255-1623-a974-5db5a8602019Q29620334-0F8DABFF-0C1A-4C39-BC6A-84FEB6166689Q30480631-75A0B5F2-E791-4040-88C7-7E498074A378Q30504688-55CBDA7C-A7CD-4C8D-B03B-F215A0C295C4Q33199387-0096E4D7-3CEB-4893-BD0A-AC160C9A4085Q33259127-5FF8ABB7-1857-4DBD-8269-0459C5C10FCDQ33572971-66049CAF-C4D0-4B3A-921C-4CBF606A3320Q33597408-9784BC68-C49C-4E5E-976A-A37434F738C7Q33698019-F6BBB61E-8DB8-4FFE-ADB0-142E237704CDQ33730171-4B579239-9CDB-41A9-B841-7D8D00A29E33Q33827752-9CC86F67-04C1-45A5-9C56-DB137FE04240Q33896026-D621792F-DAD9-438C-9275-FE66D2483EE7Q33933665-827C6AAA-32F9-459E-82C7-035E0201B558Q34015965-22585F7E-21B3-452B-B773-1A23005EF1A2Q34044406-8E9F3B18-0A33-4EA5-826B-901CB22A7BB6Q34048270-1E12560C-7321-47FA-B159-138A7B9F83E0Q34052745-9D7BA4D8-DAD3-4805-A0B9-65EE64E53E2DQ34058870-1337D06E-A78C-404D-8AB4-356429CD3864Q34228613-C4F2A3CD-1A56-4796-A752-A3D7AA05770AQ34245131-20293D4F-07B5-4419-9285-DEF577D666C3Q34269713-4503C53E-F28D-421D-BF68-A1FC57829D76Q34291894-1997AD3F-97CE-42DA-9A8E-0D79385A73F1
P50
description
American immunologist and professor
@en
Amerikaans immunoloog
@nl
US-amerikanischer Immunologe
@de
americký imunolog
@cs
amerikansk immunolog
@sv
amerykański immunolog
@pl
certificate natural
@es
immunologiste américain
@fr
immunologo e docente universitario statunitense
@it
американски имунолог и нобеловец
@mk
name
Iacobus Allison
@la
James Allison
@cs
James Allison
@ia
James P Allison
@jv
James P. Allison
@ast
James P. Allison
@ca
James P. Allison
@da
James P. Allison
@de
James P. Allison
@en
James P. Allison
@en-ca
type
label
Iacobus Allison
@la
James Allison
@cs
James Allison
@ia
James P Allison
@jv
James P. Allison
@ast
James P. Allison
@ca
James P. Allison
@da
James P. Allison
@de
James P. Allison
@en
James P. Allison
@en-ca
altLabel
James Allison
@en
James Allison
@es
James Allison
@fr
James Allison
@nl
James P Allison
@en
James P Allison
@es
James P. Allison
@cs
James Patrick Allison
@cs
Jim Allison
@en
Џејмс П. Елисон
@mk
prefLabel
Iacobus Allison
@la
James Allison
@cs
James Allison
@ia
James P Allison
@jv
James P. Allison
@ast
James P. Allison
@ca
James P. Allison
@da
James P. Allison
@de
James P. Allison
@en
James P. Allison
@en-ca